Alcoholic and Non-Alcoholic Fatty Liver Disease

Bench to Bedside
1. Auflage 2016
ISBN: 978-3-319-20537-3
Verlag: Springer International Publishing

Buch, Englisch, 372 Seiten, Format (B × H): 183 mm x 260 mm, Gewicht: 1012 g

This volume is the first text to concisely yet comprehensively cover developments for both alcoholic and nonalcoholic fatty liver disease in an organized fashion. Aspects of these two diseases covered in the book include global epidemiology and risk factors, pathogenesis, animal models, hepatic and extra-hepatic malignancies, treatment models, and current and emerging therapies.

Written by experts in the field, Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside is a valuable resource for gastroenterologists, pathologists, and hepatologists who treat patients with alcoholic and nonalcoholic fatty liver disease.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Szabo, Gyongyi

Chalasani, Naga

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hepatologie

Inhaltsverzeichnis

Epidemiology and Risk Factors for Alcoholic Liver Disease.- Global Epidemiology and Risk Factors for Non-Alcoholic Fatty Liver Disease.- Pathogenesis of Alcoholic Liver Disease.- Pathogenesis of NAFLD and NASH.- Animal Models of Alcoholic Liver Disease.- Animal Models of Nonalcoholic Fatty Liver Disease.- Genetic Basis of Alcoholic and Nonalcoholic Fatty Liver Disease.- Clinical Features, Disease Modifiers and Natural History of Alcoholic Liver Disease.- Nonalcoholic Fatty Liver Disease (NAFLD): Clinical Features, Disease Modifiers, and Natural History.- Diagnostic Approaches and Clinical Endpoints of Treatment in Alcoholic Liver Disease.- Diagnostic Considerations and Clinical Endpoints for Nonalcoholic Steatohepatitis.- Pathology of Alcoholic and Non-Alcoholic Fatty Liver Disease.- Hepatic and Extra-Hepatic Malignancies in Alcoholic Liver Disease.- Hepatic and Extra-Hepatic Malignancies in NAFLD.- Treatment of Alcoholic Liver Disease Including Emerging therapies, Novel targets and Liver transplantation.- Current and Emerging Therapies for Non-Alcoholic Fatty Liver Disease.- Nonalcoholic Fatty Liver Disease in Children.

Über Autor(innen)

Drs. Chalasani and Szabo are senior investigators in the field of fatty liver disease and have had extensive federal funding to investigate these areas. They both hold leadership positions and are recognized as experts in the field of fatty liver disease. For example, Dr. Chalasani is the lead author of the multi-society practice guideline on the diagnosis and management of nonalcoholic fatty liver disease& Dr. Szabo is the president-elect of the American Association for the Study of Liver Disease which is the largest liver society in the world. They are also actively practicing clinicians and thus aware of clinically relevant knowledge gaps in the field.